dyslipidemia
DYSLIPIDEMIA
Dyslipidemia is having an abnormal amount of lipids or fats in the blood.
Lipid profile is obtained from an individual with diabetes mellitus, coronary heart disease, cerebrovascular disease, peripheral arterial disease or other coronary heart disease risk factors or from an individual with family history or clinical evidence of familial hypercholesterolemia.
Plasma lipids are total cholesterol, high-density lipoprotein cholesterol, trigylcerides, and low-density lipoprotein cholesterol.
Evaluation of lipid profile must be performed in parallel with the risk assessment of coronary heart disease.

Dyslipidemia Drug Information

Drug Information
Cholib
fenofibrate + simvastatin

Indication: Adjunctive therapy to diet & exercise in high CV risk adult patients w/ mixed dyslipidaemia to reduce trig...

Indication: Reduction of elevated total cholesterol (total-C), LDL-C, apolipoprotein B (ApoB), total-C: HDL-C ratio trigly...

Indication: Adjunct to diet & other non-pharmacological treatment for severe hypertriglyceridaemia w/ or w/o low HDL c...

Atozet
atorvastatin + ezetimibe

Indication: Reduced risk of CV death, nonfatal MI & stroke, hospitalization for unstable angina or need for revascular...

Indication: Primary hypercholesterolaemia: Administered alone or w/ an HMG-CoA reductase inhibitor (statin) indicated as a...

Indication: Adjunct to diet for patients w/ elevated total cholesterol (total-C) & LDL-cholesterol (LDL-C), apolipopro...

Indication: Adjunct to diet & maximally tolerated statin therapy in adults w/ heterozygous familial hypercholesterolem...

Indication: Primary hypercholesterolemia: Adjunctive therapy to diet for the reduction of elevated total cholesterol (tota...

Indication: Adjunct to diet for patients w/ elevated total cholesterol (total-C), LDL-cholesterol (LDL-C), apolipoprotein ...

Indication: Hyperlipidaemia.

1  /  6
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Pearl Toh, 6 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
Elvira Manzano, 17 Nov 2020
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.